Vijay Aggarwal

Dr. Aggarwal has more than 30 years of experience in both pharmaceutical services and clinical diagnostics. Currently, Dr. Aggarwal is CEO of Vaxigenix, an early-stage pharmaceutical company developing treatments for colorectal cancer and managing partner of the Channel Group, a strategic and management advisory organization. Dr. Aggarwal was president and CEO of Aureon Laboratories Inc., a predictive pathology company offering advanced tissue analysis services to practicing physicians and the pharmaceutical industry. Before Aureon, he was president of AAI Development Services, Inc., a contract research and development services company serving the pharmaceutical and biotech industries. Before holding that position, Dr. Aggarwal was president of Quest Diagnostic Ventures, where he had responsibility for new technology, new business models, clinical trials testing, and direct-to-consumer strategies. In addition, he served on the six-member executive management team of Quest Diagnostics. Earlier in his career, Dr. Aggarwal held many positions with SmithKline Beecham Clinical Laboratories (SBCL), the clinical laboratory operations of SmithKline Beecham plc, including direct responsibility for all of SBCL’s U.S.-based laboratories as executive vice president of laboratories, responsibility for reimbursement as vice president of managed care and several general management assignments. Dr. Aggarwal serves on the boards of several privately held diagnostic testing companies, including Targeted Diagnostics and Therapeutics Inc., Lesanne Biomarkers, Mitomics LLC, Viracor-IBT Laboratories, and an IVD company, Genisphere Inc. Dr. Aggarwal holds a Ph.D. in pharmacology from the Medical College of Virginia.